A spate of new therapeutics targeting HDAC for treating various types of disorders, such as diabetes, systemic lupus erythematosus (SLE), hepatocellular carcinomas, leukemia and lymphoma, include siRNA HDAC [213], SAHA [139], PCI-24781 (Abexinostat) [214], ITF-2357 (Givinostat) [215]; MS-275 (Entinostat) [216], MGCD 0103 (Mocetinostat) [217], LBH-589 (Panobinostat) [218], FK228 (Romidepsin) [219], AGK2 [220], and PXD-101 (Belinostat) [15]. This evidence concerns the gene HDAC9 and diabetes mellitus.